Orthobiologics company Bioventus launched its initial public offering, according to a Feb. 4 news release.
The company announced 7.35 million shares of its Class A common stock, the release said. Prices are expected to be between $16 and $18 per share. Bioventus expects to grant underwriters a 30-day option to buy an additional 1.1 million shares of common stock after the initial public offering.
The company filed an initial common offering with the Securities and Exchange Commision Jan. 19. It filed an IPO in 2016 but withdrew its application two months later.